Top Stories
-
Columbia-led clinical trial addresses important barrier to opioid use disorder treatment.
Topic
-
Ryan Lawrence, MD, director of the Comprehensive Psychiatric Emergency Program, discusses what individuals can expect during an ER visit.
Topic
-
Columbia-led study hold promise for helping people find therapies that work.
Topic
-
Studies indicate that 29% to 46% of patients diagnosed with major depressive disorder show partial or no response to treatments.
Topic
Latest News
- May 17, 2022
At Columbia Cohen Center for Health and Recovery from Tick-borne diseases, Kristen Kendrick takes the time to assess the patient from multiple perspectives.
-
Source:
The New York TimesMay 17, 2022Chacku Mathai, a project director with OnTrackNY, thinks about whether, if the perfect antipsychotic existed, he would take it. “My experience is so rich,” he said, “I wouldn’t trade it for anything.”
-
Source:
ViceMay 16, 2022"There's no way that these drugs can meet the fantasized expectations that people have,” David Hellerstein, MD, a professor of clinical psychiatry at Columbia, said in reference to psychedelics.
Topic
-
Source:
ADAA GotAnxietyMay 3, 2022Jeff Cohen, a clinical psychologist at Columbia, shares an introduction to dialectical behavior therapy (DBT) as a treatment option.
Topic
-
Source:
CNN HealthApril 21, 2022Melina Wald, director of the Gender Identity Program at Columbia, says that waiting to transition can create additional psychological distress for a child.
-
Source:
Psychiatry AdvisorMarch 11, 2022Ravi N. Shah, chief innovation officer for Columbia's Department of Psychiatry, discusses the Pathways mobile app.
Topic
-
Source:
The New York TimesMarch 11, 2022“Ketamine is a medical treatment intended to address a significant illness,” such as severe depression or suicidal ideation, said Joshua Berman, assistant professor of psychiatry at Columbia.
Topic
- January 8, 2022
Columbia study finds rates are lowest among rural, Black, Hispanic, and Medicaid patients.
Topic
- December 13, 2021
New insights into genetic architecture of disease hold promise for improved risk prediction and novel drug design.
- November 17, 2021
Columbia Psychiatry is among the principal investigators in biotech Compass Pathways study of more than 200 patients.
Topic
